Ireland-based biotechnology company Aerska has raised $39 million (€32.93 million) in Series A funding to advance its brain shuttle technology for delivering RNA medicines across the blood-brain barrier to treat central nervous system diseases, according to Silicon Republic.

The latest round was led by EQT Dementia Fund and Age1, with participation from Iaso Ventures and existing investors. This brings total funds raised to $60 million (€50.66 million) since the Dublin-based company emerged from stealth in October 2025 with a $21 million (€17.73 million) seed round.

Jack O'Meara, chief executive and co-founder of Aerska alongside David Hardwicke and Stu Milstein, said: "The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration. Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer's disease and other devastating brain disorders."

The funding will advance Aerska's technology to improve delivery of RNA interference therapeutics across the blood-brain barrier for treating neurological diseases. As part of the financing, Arno de Wilde, managing director at EQT; Philip Scheltens, partner and head of the Dementia Fund at EQT; and Alex Colville, general partner at Age1, will join Aerska's board of directors.

Philip Scheltens said: "The team's strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches."

Aerska operates research facilities in both Dublin and London.

Read the complete article on how brain shuttle technology is advancing RNA therapeutics for neurological disorders.